A pooled analysis of more than 1300 patients followed for up to 4 years found that baricitinib maintained a stable safety profile, with low rates of serious adverse events, no new safety concerns, and no...
Two-year data from the long-term phase 3 ALLEGRO-LT study suggest ritlecitinib maintains long-term clinical efficacy with a manageable safety profile in patients with moderate to severe alopecia areata.
...
A recent retrospective cohort study suggests a potential long-term link between COVID-19 and increased risk for autoimmune conditions, underscoring the importance of follow-up care for those previously...
In a retrospective cohort study, researchers investigated the treatment patterns for adults in the United States with alopecia areata from 2015 to 2020.
In a recent study presented at the American Academy of Dermatology’s annual meeting, researchers examined the efficacy of various doses of an oral JAK1/JAK2 inhibitor for treating patients with...
In a post-hoc analysis of the ALLEGRO phase 2b/3 trial, researchers evaluated whether scalp, eyebrow, and eyelash hair regrowth would continue over 48 weeks in patients with alopecia areata treated with...
Researchers evaluated the efficacy of Janus kinase inhibitors in adult patients with alopecia areata. Their research was presented at the American Academy of Dermatology’s 2023 annual meeting in New...
In a recent study presented at the American Academy of Dermatology’s 2023 annual meeting, researchers examined the relationship between scalp hair loss severity and baseline distribution of eyebrow and...
